While our data show similar results using cells expressing the R175H (Hec50 endometrial cancer cells) and R248Q (OVCAR3 ovarian cancer cells) mutants, a comprehensive analysis of cells expressing other recurrent p53 GOF mutants is warranted. This evidence concerns the gene TP53 and endometrial cancer.